$NSPR
InspireMD, Inc. Stock $nspr

$nspr Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224008850 Filed on March 05, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$1.511M	$1.761M	$6.205M
YoY Change	21.95%	71.64%	20.0%
Cost Of Revenue	$1.219M	$1.256M	$4.398M
YoY Change	40.76%	51.69%	8.49%
Gross Profit	$292.0K	$505.0K	$1.807M
YoY Change	-21.72%	155.05%	61.77%
Gross Profit Margin	19.32%	28.68%	29.12%
Selling, General & Admin	$5.081M	$4.278M	$14.97M
YoY Change	74.54%	37.07%	24.53%
% of Gross Profit	1740.07%	847.13%	828.39%
Research & Development	$2.625M	$2.035M	$7.981M
YoY Change	42.43%	1.09%	2.19%
% of Gross Profit	898.97%	402.97%	441.67%
Depreciation & Amortization	$69.00K	$61.00K	$232.0K
YoY Change	25.45%	12.96%	23.4%
% of Gross Profit	23.63%	12.08%	12.84%
Operating Expenses	$7.706M	$6.313M	$22.95M
YoY Change	62.1%	22.96%	15.73%
Operating Profit	-$7.414M	-$5.808M	-$21.14M
YoY Change	69.23%	17.67%	12.99%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$382.0K	$468.0K	$1.292M
YoY Change	205.6%	293.28%	416.8%
Pretax Income	-$7.032M	-$5.340M	-$19.85M
YoY Change	65.23%	10.86%	7.52%
Income Tax		$65.00K	$65.00K
% Of Pretax Income
Net Earnings	-$7.032M	-$5.405M	-$19.92M
YoY Change	65.23%	11.56%	7.71%
Net Earnings / Revenue	-465.39%	-306.93%	-320.97%
Basic Earnings Per Share	-$0.21		-$0.82
Diluted Earnings Per Share	-$0.21	-$0.16	-$0.82
COMMON SHARES
Basic Shares Outstanding	23.46M shares	21.55M shares	24.27M shares
Diluted Shares Outstanding	34.24M shares		24.27M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$33.95M	$39.02M	$39.02M
YoY Change	163.48%	119.19%	119.19%
Cash & Equivalents	$9.389M	$9.640M	$9.640M
Short-Term Investments	$24.56M	$29.38M	$29.38M
Other Short-Term Assets	$531.0K	$578.0K	$578.0K
YoY Change	34.77%	-11.76%	-11.76%
Inventory	$2.360M	$2.106M	$2.106M
Prepaid Expenses	$531.0K	$578.0K
Receivables	$1.187M	$1.804M	$1.804M
Other Receivables	$483.0K	$648.0K	$648.0K
Total Short-Term Assets	$38.51M	$44.16M	$44.16M
YoY Change	130.56%	107.07%	107.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.186M	$1.060M	$2.533M
YoY Change	33.71%	15.59%	2.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$965.0K	$951.0K	$951.0K
YoY Change	12.34%	11.1%	11.1%
Total Long-Term Assets	$3.517M	$3.484M	$3.484M
YoY Change	9.29%	4.72%	4.72%
TOTAL ASSETS
Total Short-Term Assets	$38.51M	$44.16M	$44.16M
Total Long-Term Assets	$3.517M	$3.484M	$3.484M
Total Assets	$42.03M	$47.64M	$47.64M
YoY Change	110.97%	93.25%	93.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$659.0K	$939.0K	$939.0K
YoY Change	8.57%	42.49%	42.49%
Accrued Expenses	$1.101M	$1.115M	$4.891M
YoY Change	18.01%	101.26%	61.79%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.877M	$6.020M	$6.020M
YoY Change	11.27%	18.74%	18.74%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.064M	$2.122M	$2.122M
YoY Change	-2.27%	-3.11%	-3.11%
Total Long-Term Liabilities	$2.064M	$2.122M	$2.122M
YoY Change	-2.27%	-3.11%	-3.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.877M	$6.020M	$6.020M
Total Long-Term Liabilities	$2.064M	$2.122M	$2.122M
Total Liabilities	$6.941M	$8.142M	$8.142M
YoY Change	6.87%	12.15%	12.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$228.5M	-$221.5M
YoY Change	11.02%	9.88%
Common Stock	$2.000K	$2.000K
YoY Change	100.0%	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$35.09M	$39.50M	$39.50M
YoY Change
Total Liabilities & Shareholders Equity	$42.03M	$47.64M	$47.64M
YoY Change	110.97%	93.25%	93.25%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$7.032M	-$5.405M	-$19.92M
YoY Change	65.23%	11.56%	7.71%
Depreciation, Depletion And Amortization	$69.00K	$61.00K	$232.0K
YoY Change	25.45%	12.96%	23.4%
Cash From Operating Activities	-$5.064M	-$4.177M	-$16.38M
YoY Change	4.82%	30.74%	5.37%
INVESTING ACTIVITIES
Capital Expenditures	$195.0K	$215.0K	$381.0K
YoY Change	680.0%	126.32%	-19.45%
Acquisitions
YoY Change
Other Investing Activities	$5.012M	$179.0K	-$15.71M
YoY Change	12.03%	-95.5%	-276.25%
Cash From Investing Activities	$4.817M	-$36.00K	-$16.09M
YoY Change	8.27%	-100.93%	-290.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000	$37.53M
YoY Change			-26910.0%
NET CHANGE
Cash From Operating Activities	-$5.064M	-4.177M	-$16.38M
Cash From Investing Activities	$4.817M	-36.00K	-$16.09M
Cash From Financing Activities		0.000	$37.53M
Net Change In Cash	-$251.0K	-4.213M	$5.008M
YoY Change	-37.87%	-709.7%	-167.93%
FREE CASH FLOW
Cash From Operating Activities	-$5.064M	-$4.177M	-$16.38M
Capital Expenditures	$195.0K	$215.0K	$381.0K
Free Cash Flow	-$5.259M	-$4.392M	-$16.76M
YoY Change	8.3%	33.5%	4.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001433607
CY2023Q4	NSPR	Shortterm Bank Deposits ShorttermBankDeposits		usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023	NSPR	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised		usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2022	NSPR	Changes In Fair Value Of Marketable Securities ChangesInFairValueOfMarketableSecurities		usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
CY2022	NSPR	Proceeds From Matured Marketable Securities ProceedsFromMaturedMarketableSecurities		usd
CY2023	NSPR	Issuance Costs Of At Market Offering IssuanceCostsOfAtMarketOffering		usd
CY2022	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		usd
CY2022	NSPR	Noncash Lease Incentive NoncashLeaseIncentive		usd
CY2022	NSPR	Decrease In Rightofuse Assets And Lease Liabilities Due To Shortening Lease Term DecreaseInRightofuseAssetsAndLeaseLiabilitiesDueToShorteningLeaseTerm		usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccountsPayableOtherCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccountsPayableOtherCurrent
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-35731
CY2023	dei	Entity Registrant Name EntityRegistrantName	InspireMD, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2123838
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	4 Menorat Hamaor St.
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Tel Aviv
CY2023	dei	Entity Address Country EntityAddressCountry	IL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	6744832
CY2023	dei	City Area Code CityAreaCode	(888)
CY2023	dei	Local Phone Number LocalPhoneNumber	776-6804
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	NSPR
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	46130594	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23456590	shares
CY2023	dei	Auditor Firm AuditorFirmId	1309
CY2023	dei	Auditor Name AuditorName	Kesselman & Kesselman
CY2023	dei	Auditor Location AuditorLocation	Tel-Aviv, Israel
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9640000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4632000	usd
CY2022Q4	NSPR	Shortterm Bank Deposits ShorttermBankDeposits	13171000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	29383000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1804000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1034000	usd
CY2023Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	648000	usd
CY2022Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	213000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	578000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	655000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2106000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1621000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	44159000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	21326000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1060000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	917000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1473000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1554000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	951000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	856000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	3484000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	3327000	usd
CY2023Q4	us-gaap	Assets Assets	47643000	usd
CY2022Q4	us-gaap	Assets Assets	24653000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	939000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	659000	usd
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	5081000	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	4411000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6020000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5070000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1038000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1195000	usd
CY2023Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1084000	usd
CY2022Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	995000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2122000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2190000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	8142000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7260000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21841215	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21841215	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8330918	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8330918	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	261000000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	218977000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-221501000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-201585000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	39501000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17393000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47643000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24653000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6205000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5171000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4398000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4054000	usd
CY2023	us-gaap	Gross Profit GrossProfit	1807000	usd
CY2022	us-gaap	Gross Profit GrossProfit	1117000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7981000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7810000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3865000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3664000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11104000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8356000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	22950000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	19830000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-21143000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-18713000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1292000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	250000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19851000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18463000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	28000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-19916000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18491000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.35
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.35
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24268181	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24268181	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7871814	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7871814	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	33532000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18491000	usd
CY2022	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	10832	shares
CY2022	NSPR	Sharebased Compensation Related To Restricted Stock Restricted Stock Units And Stock Options Award Net Of Forfeitures SharebasedCompensationRelatedToRestrictedStockRestrictedStockUnitsAndStockOptionsAwardNetOfForfeitures	2352000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17393000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17393000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-19916000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4635000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37534000	usd
CY2023	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	29695	shares
CY2023	NSPR	Sharebased Compensation Related To Restricted Stock Restricted Stock Units And Stock Options Award Net Of Forfeitures SharebasedCompensationRelatedToRestrictedStockRestrictedStockUnitsAndStockOptionsAwardNetOfForfeitures	4490000	usd
CY2023	NSPR	Sharebased Compensation Related To Restricted Stock Restricted Stock Units And Stock Options Award Net Of Forfeitures SharebasedCompensationRelatedToRestrictedStockRestrictedStockUnitsAndStockOptionsAwardNetOfForfeitures	4490000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	39501000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-19916000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18491000	usd
CY2023	us-gaap	Depreciation Depreciation	232000	usd
CY2022	us-gaap	Depreciation Depreciation	188000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	6000	usd
CY2023	NSPR	Changes In Fair Value Of Marketable Securities ChangesInFairValueOfMarketableSecurities	739000	usd
CY2023	NSPR	Change In Liability For Employees Rights Upon Retirement ChangeInLiabilityForEmployeesRightsUponRetirement	-89000	usd
CY2022	NSPR	Change In Liability For Employees Rights Upon Retirement ChangeInLiabilityForEmployeesRightsUponRetirement	57000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-58000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-131000	usd
CY2023	NSPR	Change In Right Of Use Asset And Leasing Liability ChangeInRightOfUseAssetAndLeasingLiability	-62000	usd
CY2022	NSPR	Change In Right Of Use Asset And Leasing Liability ChangeInRightOfUseAssetAndLeasingLiability	60000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4490000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2352000	usd
CY2023	NSPR	Interest Income From Shortterm Bank Deposits InterestIncomeFromShorttermBankDeposits	-171000	usd
CY2022	NSPR	Interest Income From Shortterm Bank Deposits InterestIncomeFromShorttermBankDeposits	135000	usd
CY2023	NSPR	Loss Gain On Amounts Funded In Respect Of Employee Rights Upon Retirement Net LossGainOnAmountsFundedInRespectOfEmployeeRightsUponRetirementNet	16000	usd
CY2022	NSPR	Loss Gain On Amounts Funded In Respect Of Employee Rights Upon Retirement Net LossGainOnAmountsFundedInRespectOfEmployeeRightsUponRetirementNet	-135000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-77000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-7000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	770000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-190000	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	435000	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	48000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	485000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	478000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	280000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-234000	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	532000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	958000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16376000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15542000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	381000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	473000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	12000	usd
CY2023	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	5500000	usd
CY2022	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	19000000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	34644000	usd
CY2023	NSPR	Proceeds From Matured Marketable Securities ProceedsFromMaturedMarketableSecurities	6000000	usd
CY2023	NSPR	Amounts Withdrawn In Respect Of Employee Rights Upon Retirement Net AmountsWithdrawnInRespectOfEmployeeRightsUponRetirementNet	79000	usd
CY2022	NSPR	Amounts Withdrawn In Respect Of Employee Rights Upon Retirement Net AmountsWithdrawnInRespectOfEmployeeRightsUponRetirementNet	86000	usd
CY2023	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	18500000	usd
CY2022	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	28000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16092000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8441000	usd
CY2022	NSPR	Issuance Costs Of At Market Offering IssuanceCostsOfAtMarketOffering	140000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4635000	usd
CY2023	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	37534000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	37534000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-140000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-58000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-131000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5008000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7372000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4632000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12004000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9640000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4632000	usd
CY2023	NSPR	Noncash Acquisition Of Right Of Use Assets By Means Of Lease Liabilities NoncashAcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities	419000	usd
CY2022	NSPR	Noncash Acquisition Of Right Of Use Assets By Means Of Lease Liabilities NoncashAcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities	835000	usd
CY2023	NSPR	Noncash Lease Incentive NoncashLeaseIncentive	45000	usd
CY2023	NSPR	Decrease In Rightofuse Assets And Lease Liabilities Due To Shortening Lease Term DecreaseInRightofuseAssetsAndLeaseLiabilitiesDueToShorteningLeaseTerm	131000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80A_eus-gaap--NatureOfOperations_zpIe2aA7GS44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - <span id="xdx_820_zyKBqwKfLbql">DESCRIPTION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.15in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InspireMD, Inc., a Delaware corporation (the “Company”), together with its subsidiaries, is a medical device company focusing on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of complex vascular and coronary disease. MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s carotid product (CGuard™ EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company ceased sales of the Company’s MGuard Prime EPS in the beginning of 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company market its products through distributors in international markets, mainly in Europe.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the date of issuance of these consolidated financial statements, the Company has the ability to fund its planned operations for at least the next 12 months. However, the Company expects to continue incurring losses and negative cash flows from operations until its product, CGuard™ EPS, reaches commercial profitability. Therefore, in order to fund the Company’s operations until such time that the Company can generate substantial revenues, the Company may need to raise additional funds.</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status of European Medical Device Regulation for marketing CGuard EPS in countries requiring the CE Mark.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the European Union (“EU”) nations, medical devices must obtain a CE mark before they may be placed on the market. In order to obtain and maintain the CE mark, the Company must comply with EU law on medical devices, which, until May 26, 2021 was governed by the Medical Device Directive 93/42/EEC (“MDD”), by presenting comprehensive technical files for the Company’s products demonstrating safety and efficacy of the product to be placed on the market and passing initial and annual quality management system audit as per ISO 13485 standard by a European Notified Body. The Company has obtained ISO 13485 quality system certification and CGuard EPS that the Company currently distribute into the European Union, displays the required CE mark. In order to maintain certification, the Company is required to pass an annual surveillance audit conducted by Notified Body auditors. The European Union replaced the MDD with the new European Medical Device Regulation (MDR 2017/745) (“MDR”) regulations. The MDR entered into force after a transitional period of three years and a one year extension of that transition period due to the COVID-19 pandemic on May 26, 2021 and which changes several aspects of the regulatory framework in the EU. Manufacturers had the duration of the transition period to update their technical documentation and processes to meet the new requirements in order to obtain a CE Mark.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the Company’s specific case, the Company’s CE mark for CGuard EPS under the MDD expired on November 12, 2022. On February 14, 2023, the Company received a derogation per Article 97 paragraph 1 of Regulation 2017/745 from the Agency for Medicines and Health Products (FAMHP) allowing the Company to continue marketing CGuard EPS in the EU until August 15, 2023. Subsequently, on March 20, 2023 Regulation (EU) 2023/607 was published allowing the Company to continue marketing CGuard EPS in EU countries under the MDD directive until December 31, 2027.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2024, the Company received CE mark recertification for the CGuard™ EPS under the EU’s Medical Device Regulation regulatory framework and can market Cguard permanently in EU countries as long as the Company is able to maintain its regulatory approvals.</span></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.65in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.15in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks Related to Our Operations in Israel including the recent attack by Hamas and other terrorist organizations from the Gaza Strip and Israel’s war against them.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2023, Israel was attacked by a terrorist organization and entered a state of war. As of the date of these consolidated financial statements, the war in Israel is ongoing and continues to evolve. The Company operations including the production facility are located in Israel. Currently, such activities in Israel remain largely unaffected. During the year ended December 31, 2023, the impact of this war on the Company’s results of operations and financial condition was immaterial, but such impact may increase, which could be material, as a result of the continuation, escalation or expansion of such war.</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>d.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks Related to the Geopolitical and Military Tensions Between Russia and Ukraine in Europe</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company derived approximately <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--StatementGeographicalAxis__custom--RussiaAndBelarusMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zStYvD2Mpaz4" title="Sales percentage">13.5</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__srt--StatementGeographicalAxis__custom--RussiaAndBelarusMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zwiVI3QTAwla" title="Sales percentage">12.1</span>% in the years ended December 31, 2023 and 2022, respectively, of total sales in Russia and Belarus. The escalation of geopolitical instability in Russia and Ukraine as well as currency fluctuations in the Russian Ruble could negatively impact the Company’s operations, sales, and future growth prospects in that region.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the crisis in Ukraine, the United States and the EU have implemented sanctions against certain Russian individuals and entities and have made it more difficult for the Company to collect on outstanding accounts receivable from customers in this region. The Company cannot provide assurance that potential future changes in sanctions will not have a material impact on the Company’s operations in Russia and Belarus or on the Company’s financial results.</span></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INSPIREMD, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_znT9YjbeZ9da" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zgSa0GnchsB2">Use of estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations and assessing the likelihood of exercise of options to extend the lease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zJRMTUkXziFc" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>g.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zyX99t0YbLRi">Concentration of credit risk and allowance for doubtful accounts</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that may potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and short-term bank deposits, which are deposited in major financially sound institutions in the U.S, Israel and Germany, and trade accounts receivable and other receivables. The Company’s trade accounts receivable is derived from revenues earned from customers from various countries. The Company performs ongoing credit evaluations of its customers’ financial condition and, requires no collateral from its customers. The Company also has a credit insurance policy for some of its customers. The Company maintains the allowance for estimated losses resulting from the inability of the Company’s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company’s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations. The allowance for expected credit losses was immaterial during the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> </p>
CY2023	NSPR	Research And Development Expense Including Us Based Clinical Trial Cost ResearchAndDevelopmentExpenseIncludingUSBasedClinicalTrialCost	3300000	usd
CY2022	NSPR	Research And Development Expense Including Us Based Clinical Trial Cost ResearchAndDevelopmentExpenseIncludingUSBasedClinicalTrialCost	4468000	usd
CY2023	us-gaap	Significant Change In Unrecognized Tax Benefits Nature Of Event SignificantChangeInUnrecognizedTaxBenefitsNatureOfEvent	the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
CY2023	us-gaap	Advertising Expense AdvertisingExpense	426000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	359000	usd
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	9612502	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	3054086	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	355951	shares
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3100000	usd
CY2023Q4	us-gaap	Securities Borrowed Fair Value Disclosure SecuritiesBorrowedFairValueDisclosure	28727000	usd
CY2023Q4	NSPR	Marketable Securities Maturities Within One Year Fair Value MarketableSecuritiesMaturitiesWithinOneYearFairValue	24523000	usd
CY2023Q4	NSPR	Marketable Securities Maturities After One Year Through Two Years Fair Value MarketableSecuritiesMaturitiesAfterOneYearThroughTwoYearsFairValue	4860000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	29383000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	34644000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6000000	usd
CY2023	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	38000	usd
CY2023	NSPR	Changes In Fair Value Marketable Securities ChangesInFairValueMarketableSecurities	777000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	29383000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2825000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2040000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1908000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1060000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	917000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	232000000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	188000000	usd
CY2023	NSPR	Percentage Of Monthly Deposits On Salary PercentageOfMonthlyDepositsOnSalary	0.0833	pure
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	433000000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	442000000	usd
CY2023	NSPR	Schedule Of Supplemental Information Related To Leases ScheduleOfSupplementalInformationRelatedToLeases	<p id="xdx_895_ecustom--ScheduleOfSupplementalInformationRelatedToLeases_ziRiz2eTbM6l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental information related to leases are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zVC3SDg4rb24" style="display: none">SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 1in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20231231_zi1fwVkU2Nch" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20221231_zH0UunBEqICi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($ in thousands)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zW5d8mnI45Hg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1.5pt">Operating lease right-of-use assets</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">1,473</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">1,554</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zdznPPFqW4ak" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span id="xdx_904_eus-gaap--OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20231231_z1vxJWDe05k4" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2023%23AccountsPayableOtherCurrent"><span id="xdx_908_eus-gaap--OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20221231_zGGkWqbuwMOf" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2023%23AccountsPayableOtherCurrent"><span style="-sec-ix-hidden: xdx2ixbrl0641"><span style="-sec-ix-hidden: xdx2ixbrl0642">Current Operating lease liabilities</span></span></span></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(557</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(419</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iNI_pn3n3_di_zjb5oP8xyWzh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Non-current operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,038</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,195</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other information:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 35.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 1in"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1.5pt">Operating cash flows from operating leases (cash paid in thousands)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingLeasePayments_iN_pn3n3_di_c20230101__20231231_zmnIJT6Rgf9a" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Operating cash flows from operating leases (cash paid in thousands)">(429</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingLeasePayments_iN_pn3n3_di_c20220101__20221231_zvbGT6T3Van4" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Operating cash flows from operating leases (cash paid in thousands)">(436</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Weighted Average Remaining Lease Term</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zGfZBScZg9nd" title="Weighted average remaining lease">3</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zvoO2azwpXy1" title="Weighted average remaining lease">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Weighted Average Discount Rate</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zgJxXqVCsEll" title="Weighted average discount rate">9.73</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zEnmptHftA7f" title="Weighted average discount rate">8.69</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> </table>
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1473000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1554000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	557000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	419000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1038000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1195000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	429000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	436000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0973	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0869	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	579000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	584000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	653000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1816000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	221000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1595000	usd
CY2021Q1	NSPR	Direct Distribution Regulatory Cost Percentage DirectDistributionRegulatoryCostPercentage	0.50	pure
CY2021Q1	us-gaap	Distribution Made To Limited Partner Cash Distributions Declared DistributionMadeToLimitedPartnerCashDistributionsDeclared	1000000	usd
CY2023Q4	NSPR	Direct Distribution Regulatory Cost Percentage DirectDistributionRegulatoryCostPercentage	0.50	pure
CY2023	NSPR	Stock Issued During Period Shares Stock Warrants Exercised StockIssuedDuringPeriodSharesStockWarrantsExercised	307260	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	53396008	shares
CY2023Q4	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	155000000	shares
CY2023Q4	NSPR	Capital Stock Par Or Stated Value Per Share CapitalStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7731618	shares
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	2171365	shares
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P9Y10D
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	300376	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0358	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0473	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0179	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0288	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.0962	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.2561	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.2743	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.3093	pure
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4490000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2352000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	55000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.21	pure
CY2016Q4	NSPR	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate1 EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate1	0.12	pure
CY2016Q4	NSPR	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate2 EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate2	0.06	pure
CY2023	NSPR	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate2 EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate2	0.04	pure
CY2023	NSPR	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate3 EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate3	0.90	pure
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	54000000	usd
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	35000000	usd
CY2023Q4	NSPR	Net Loss Carryforwards Percentage NetLossCarryforwardsPercentage	0.80	pure
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19851000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18463000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40071000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	39212000	usd
CY2023	NSPR	Deferred Tax Assets Losses During Year Including Foreign Exchange Rate Effect DeferredTaxAssetsLossesDuringYearIncludingForeignExchangeRateEffect	2580000	usd
CY2022	NSPR	Deferred Tax Assets Losses During Year Including Foreign Exchange Rate Effect DeferredTaxAssetsLossesDuringYearIncludingForeignExchangeRateEffect	859000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	42651000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40071000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	106000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	89000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	62000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	17000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	168000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	106000	usd
CY2023Q4	NSPR	Deferred Tax Assets Tax Deferred Expense Provision For Vacation And Recreation Pay DeferredTaxAssetsTaxDeferredExpenseProvisionForVacationAndRecreationPay	68000	usd
CY2022Q4	NSPR	Deferred Tax Assets Tax Deferred Expense Provision For Vacation And Recreation Pay DeferredTaxAssetsTaxDeferredExpenseProvisionForVacationAndRecreationPay	45000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1691000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1452000	usd
CY2023Q4	NSPR	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Operating Lease Right Of Use Assets DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOperatingLeaseRightOfUseAssets	-339000	usd
CY2022Q4	NSPR	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Operating Lease Right Of Use Assets DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOperatingLeaseRightOfUseAssets	-357000	usd
CY2023Q4	NSPR	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Operating Lease Liabilities DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOperatingLeaseLiabilities	367000	usd
CY2022Q4	NSPR	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Operating Lease Liabilities DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOperatingLeaseLiabilities	371000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3492000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3021000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	37342000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35507000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Severance Payments DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments	30000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Severance Payments DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments	32000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	42651000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	40071000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	42651000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40071000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	210000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	179000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	562000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	510000	usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1334000	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	932000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2106000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1621000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2188000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1853000	usd
CY2023Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	287000	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	197000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1115000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	554000	usd
CY2023Q4	NSPR	Clinical Trial Accrual Current ClinicalTrialAccrualCurrent	744000	usd
CY2022Q4	NSPR	Clinical Trial Accrual Current ClinicalTrialAccrualCurrent	1258000	usd
CY2023Q4	NSPR	Accrued Operating Lease Liabilities Current AccruedOperatingLeaseLiabilitiesCurrent	557000	usd
CY2022Q4	NSPR	Accrued Operating Lease Liabilities Current AccruedOperatingLeaseLiabilitiesCurrent	419000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	190000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	130000	usd
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	5081000	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	4411000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6205000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5171000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6205000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5171000	usd

Files In Submission

Name	View Source	Status
0001493152-24-008850-index-headers.html	Edgar Link	pending
0001493152-24-008850-index.html	Edgar Link	pending
0001493152-24-008850.txt	Edgar Link	pending
0001493152-24-008850-xbrl.zip	Edgar Link	pending
ex10-62.htm	Edgar Link	pending
ex10-62_001.jpg	Edgar Link	pending
ex10-62_002.jpg	Edgar Link	pending
ex10-62_003.jpg	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-1.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nspr-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
nspr-20231231_cal.xml	Edgar Link	unprocessable
nspr-20231231_def.xml	Edgar Link	unprocessable
nspr-20231231_lab.xml	Edgar Link	unprocessable
nspr-20231231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NSPR
InspireMD, Inc. Stock $nspr

2024 Q1 Form 10-K Financial Statement

#000149315224008850 Filed on March 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NSPR InspireMD, Inc. Stock $nspr

2024 Q1 Form 10-K Financial Statement

#000149315224008850 Filed on March 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NSPR
InspireMD, Inc. Stock $nspr